SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD), announced today that the U.S. Government has disclosed plans to support research, development, acquisition, storage/maintenance, deployment, and utilization of broad-spectrum treatment countermeasures able to address multiple bioterror and pandemic threats. The preeminent focus of prior government initiatives has been fixed defenses attempting to align a specific treatment with each known bioterror and pandemic threat. Aethlon Medical believes its Hemopurifier® treatment technology is a leading broad-spectrum countermeasure candidate. The Hemopurifier® is designed to assist in the treatment of multiple bioterror threats, including Smallpox, Ebola, Marburg, Lassa fever, and potentially genetically engineered viruses purposely developed to defeat traditional drug and vaccine therapy.
